Alexandria Venture Investments was among the participants in a series B round which will support clinical trials for Acrivon's lead oncology drug candidate.

US-based cancer drug developer Acrivon Therapeutics secured $100m yesterday in a series B round backed by life science real estate investment trust Alexandria Real Estate Equities. Investment manager Wellington Management co-led the round with Surveyor Capital, a subsidiary of wealth management firm Citadel, while Alexandria took part through its venture capital vehicle, Alexandria Venture Investments.…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.